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OBJECTIVES: Achieving optimal blood glucose control while avoiding hypoglycae-
mia forms the foundation of diabetes management. The objective of this study was
to undertake a equilibrium analysis to identify the level of HbA1c reduction re-
quired to achieve the same quality of life benefit as achieved by avoiding events of
non-severe symptomatic hypoglycemia (NSHE). METHODS: This study used the
IMS Core Diabetes Model (CDM), a validated and established diabetes model, to
explore the relationship between the avoidance of NSHE, HbA1c reduction and
quality-adjusted life expectancy (QALE). Scenario analysis (SA) comparing rates of
NSHE ranging from 25 to 250 events per 100 patient years with no HbA1c effect (i)
and comparing increasing difference in HbA1c change with no effect on NSHE (ii)
were conducted. The model was run over a lifetime and benefits were discounted at
3.0%. Sensitivity analysis was conducted on the disutility of symptomatic
hypoglycemia. RESULTS: The QALE gain associated with avoiding 1 NSHE per pa-
tient per year was 0.06; incremental QALE per event avoided changed in sensitivity
analyses to 0.035, 0.124 and 0.212 quality adjusted life years for assumed disutilities
of -0.0029, -0.0107 and -0.0184, respectively. The impact of HbA1c reduction on
QALE gain ranged from 0.0112 to 0.1171 for changes between 0.1% and 1.0% points,
respectively. The HbA1c reduction required to achieve equivalent QALE benefit as
the avoidance of one NSHE per patient per year was 0.54% in the base case analysis
(NSHE disutility of -0.0052) and 0.33%, 1.08% and 1.84% in SA for NSHE disutilities of
0.0029, -0.0107 and -0.0184, respectively. CONCLUSIONS: HbA1c change and re-
duced NSHE are key drivers of cost effectiveness. This analysis is noteworthy as it
demonstrates the significant contribution to QALE associated with the avoidance
of NSHE. The avoidance of NSHE is at least as powerful a driver of QALE as lowering
HbA1c.
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ECONOMIC CONSEQUENCES OF SEVERE HYPOGLYCAEMIA – PRELIMINARY
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OBJECTIVES: Severe hypoglycaemic events (SHEs) are most commonly defined as
symptomatic, severe hypoglycaemia in which a patient needs either assistance
from another individual or professional medical care. SHEs impose a substantial
economic burden on health care systems. The aim of our analysis is to assess the
total number and corresponding costs (both direct and indirect) of SHEs in either
type 1 or 2 diabetes in five Central European countries in a unified approach in order
to compare results and main drivers of differences. METHODS: SHEs were further
divided into low (only help provided on-site by a non-medical professional), me-
dium (emergency care or consultation by a physician or other medical professional)
and high (admission to hospital) resource consumption episodes. Data on unit
costs and resource use for low, medium and high resource consumption SHEs were
collected for each country based on published literature and expert opinions. The
risks of SHEs were determined separately for individual groups of anti-diabetic
drugs used in monotherapy or in a combined treatment. Subsequently the eco-
nomic model was developed to combine epidemiological data and drug use pat-
terns for Czech Republic, Croatia, Hungary, Poland and Slovenia, to estimate the
number of SHEs and resulting indirect and direct costs from payer’s perspective in
each of the participating countries. RESULTS: Low resource consumption SHEs
were rarely associated with resources used that were covered by public payers.
Medium resource consumption SHEs contributed most to total direct costs. Hospi-
tal admissions directly associated with SHEs although not common, present a
considerable expense to the health care system. The total number and correspond-
ing costs of SHEs were different for participating countries as a consequence of
diverse unit medical costs and sulphonylureas use. CONCLUSIONS: Our prelimi-
nary estimates for Central European countries suggested substantial economic
burden associated with SHE and large differences between the countries.
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OBJECTIVES: Fear of hypoglycemia influences Health-Related Quality of Life
(HRQoL) in type 2 diabetes mellitus (T2DM) patients implying changes in clinical
management. The aim of the study is to explore the way that fear for hypoglycemia
modifies HRQoL in T2DM patients in Spain. METHODS: Observational, cross-sec-
tional, multicentre design. T2DM patients diagnosed from at least 1 year were
recruited consecutively. Use of research tools: 1) Audit of Diabetes-Dependent Quality
of Life/ADDQoL questionnaire [-9 to 9, more negative scores indicate greater neg-
ative impact of diabetes on QoL]; 2) Worry Subscale of the Hypoglycaemic Fear Survey-II
(HFS-II) [0-72, higher scores indicate increased fear]; 3) Visual Analogue Scales
(VAS) measuring fear and impact of hypoglycemia [0-10, higher scores indicate
greater fear and impact of hypoglycemia]. RESULTS: A total of 3,812 patients (661
health care centers; 17 regions) participated in the study [men (53.57%); mean(SD)
age 63.70(11.37) years; retired (43.02%); mean(SD) time from T2DM diagnosis
9.67(6.91) years. 44.88% referred at least one episode of hypoglycemia in the previ-
ous six months, more frequent (40.50%) and severe (43.37%) in the morning. Mean
(SD) HFS-II subscale score was higher in patients who reported hypoglycemic epi-
sodes during the previous six months [31.32(15.71)] compared to those who did not
[18.85(16.03)](p0.0001). Mean (SD) ADDQoL scores showed a greater significant
negative impact of T2DM on QoL in patients with hypoglycemia [-2.48(1.61)] than in
those with no previous episodes [-1.64(1.36)](p0.0001). They also scored signifi-
cant higher the influence of fear for hypoglycemia on everyday life [VAS mean (SD)
5.19(2.68)], on daily activities [VAS mean (SD) 5.98(2.59)] and in relation to other
health problems [VAS mean (SD) 5.50(2.72)] compared to patients with no previous
hypoglycemia episodes [VAS mean (SD) 1.73(2.30); 2.89(2.82) and 2.73(2.72),
respectively](p0.0001). CONCLUSIONS: Fear of hypoglycemia negatively influ-
ences T2DM patients HRQoL particularly when episodes of hypoglycemia had
taken place during the previous six months.
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OBJECTIVES: Despite the negative impact on patients’ quality of life, limited data
across countries are available on hypoglycaemia in insulin-treated diabetes pa-
tients in ‘real-world’ settings. This study investigated rates of self-reported non-
severe hypoglycaemic events (NSHE) and reporting of hypoglycaemia to general
practitioners (GPs) or specialists.METHODS:Diabetes patients (type 1 [T1] and type
2 [insulin regimen: basal only, T2BOT; basal-bolus, T2BB; and other, T2O]) in Aus-
tria, Denmark, Finland, Norway, The Netherlands, Sweden and Switzerland were
recruited, mainly via online panels, to complete four questionnaires at seven-day
intervals. Data on patient demographics, hypoglycaemia-related behaviour and
NSHE in the preceding seven days were collected. NSHE was defined as an event
with symptoms of hypoglycaemia, with or without blood glucose measurement
(BGM), or low BGM without symptoms, which the patient could manage without
assistance. RESULTS: A total of 11,790 patient-week records were collected from
3958 patients (57% completed all four questionnaires). Mean insulin treatment
duration was 19, 5, 9 and 7 years for T1, T2BOT, T2BB and T2O, respectively. Mean
HbA1c was 7.7% (T1) and 7.6% (T2). Mean self-reported NSHE/patient-week was 1.7
in T1 (Austria: 1.6, Denmark: 1.9, Finland: 1.3, Norway: 1.8, The Netherlands: 2.0,
Sweden: 2.0, Switzerland: 1.4), 0.4 in T2BOT (Austria: 0.3, Denmark: 0.4, Finland: 0.2,
Norway: 0.4, The Netherlands: 0.5, Sweden: 0.4, Switzerland: 0.4) and 0.7 in T2BB
(Austria: 0.5, Denmark: 0.7, Finland: 0.5, Norway: 1.0, The Netherlands: 0.7, Sweden:
0.9, Switzerland: 0.6). Night-time NSHE was 22% (T1), 25% (T2BOT) and 17% (T2BB)
of NHSEs. Overall 60% of patients stated that they rarely or never reported NSHEs to
their GP/specialist. Similarly, 22% (overall) were not routinely asked by their GP/
specialist about hypoglycaemia. CONCLUSIONS: NSHE are common amongst in-
sulin-treated patients and rates are comparable in all countries investigated.
Events are often not reported to patients’ GP/specialist. The real burden of hypo-
glycaemia may therefore be underestimated.
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